Location: Home >> Status of Hypoglycemia in Insulin Intensive Treatment
Diabetes mellitus is a global health problem that deserves attention. Its pathogenesis is mainly caused by the decrease of pancreatic β cell level and insulin resistance. Some cellular inflammatory factors are also involved in the formation of T2DM. For T2DM patients with significantly elevated blood glucose at initial diagnosis and poorly controlled blood glucose for a long time, short-term intensive insulin treatment has a better effect. The most commonly used short-term intensive insulin treatment in clinic include continuous subcutaneous injection of insulin pump (CSII), multiple subcutaneous injection of insulin (MSII) and premixed insulin analogizes injected subcutaneously 3 times a day. The incidence of hypoglycemic events, including glycopenia, hypoglycemic reaction and hypoglycemia, also increased with the effective elimination of glucotoxicity of insulin intensive therapy. Different hypoglycemia grades can cause different hypoglycemia symptoms and affect the prognosis of diabetic patients. We should be sensitive to hypoglycemia events and timely implement reasonable intervention measures to protect the islet function of diabetic patients to the greatest extent.
[1] Shin So, Seo HJ, Park H, et al. Effects of mulberry leaf extract on blood glucose and serum lipid profiles in patients with type 2 diabetes mellitus: a systematic review [J]. EurJ Integrat Med, 2016, 8(5):602-8.
[2] Yang X, Chen GF, Liu C. Current situation and prospect of reversing type 2 diabetes mellitus [J]. Chinese Journal of Diabetes, 201, 13(7): 666-72.
[3] CHON S, RHEE S Y, AHN K J, et al. Long-term effects on glycaemic control and β-cell preservation of early intensive treatment in patients with newly diagnosed type 2 diabetes: A multicentre randomized trial [J]. Diabetes Obes Metab, 2018, 20(5):1121-30.
[4] Weng J. Short-term insulin intensive treatment could be the preferred option for new onset type 2 diabetes mellitus patients with HbA1c>9 [J]. Diabetes, 2017, 9(10): 890-93.
[5] Lin S, CHen M, CHen W, et al. A randomized trial of insulin glargine plus oral hypoglycemic agents versus continuous subcu-taneousinsulin infusion to treat newly diagnosed type 2 diabetes [J]. Diabetes Res, 2018, 2018:2791584.
[6] Morling JR, Fallowfield JA, Williamson Rm, et al. γ-Glutamyltrans ferase, but not markers of hepatic fibrosis, is associated with cardiovascular disease in older people with type 2 diabetes mellitus the Edinburgh Type 2 Diabetes Study [J]. Diabetologia, 2015, 58(7):1484.
[7] Kaneto H. Pancreatic p-cell glucose toxicity in type 2 diabetes mellitus [J]. Curr Diabetes Rev, 2015, 11:2-6.
[8] UK Prospective Diabetes Study (UKPDS Group). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [J]. Lancet, 1998, 352: 837-53.
[9] Rodriguez-Gutierrez R, Lipska KJ, McCoy RG, et al. Hypoglycemia as an indicator of good diabetes care [J]. BMJ, 2016, 352:i1084.
[10] Diabetes Society of Chinese Medical Association. Guidelines for the prevention and treatment of type 2 diabetes in China (2020 edition) [J]. Chinese Journal of Diabetes, 13(04):315-409.
[11] Ikowa H, Glaser B, Tungkale A, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment [J]. Diabetes Care, 1997, 20:1353-56.
[12] Action to Control Cardiovascular Risk in Diabetes Study Group, Turnbull FM, Abraira C, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes [J]. Diabetologia, 2009, 52:2288-98.
[13] Origin Trial Investigators, Gerstein HC, Bosch J, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia [J]. The New England journal of medicine, 2012, 367:319-28.
[14] Hanefeld M, Fleischmann H, Schiffhorst G, et al. Predictors of response to early basal insulin treatment in patients with type 2 diabetes – the EARLY experience [J]. Diabetes technology & therapeutics, 2014, 16:241-6.
[15] Pistrosch F, Kohler C, Schaper F, et al. Effects of insulin glargine versus metformin on glycemic variability, microvascular and beta-cell function in early type 2 diabetes [J]. Acta diabetologica, 2013, 50:587-95.
[16] Alvarsson M, Berntorp K, Fernqvist-Forbes E, et al. Effects of insulin versus sulphonylurea on beta-cell secretion in recently diagnosed type 2 diabetes patients: a 6-year follow-up study [J]. The review of diabetic studies: RDS, 2010, 7:225-32.
[17] Chinese Medical Association Endocrinology Branch, Chinese Medical Association Diabetes Branch, Chinese Medical Associ-ation Endocrinology and Metabolism Physicians Branch. Chinese insulin pump treatment guidelines (2021 edition) [J]. Chinese Journal of Endocrinology and Metabolism, 37(08):679-701.
[18] Yuan SY, Yang GF. Hypoglycemia [J]. Journal of Endocrinology, 2005, 25(1):70.
[19] American Diabetes Association, Erratum, Glycemic Targets, et al. In Standards of Medical Care in Diabetes-2017 [J]. Diabetes Care, 2017, 40(Suppl.1):S48-S56.
[20] Zinman B, Marso SP, Christiansen E, et al. Hypo glycemia, Cardiovascular Outcomes, and Death: The LEADER Expe [J]. Diabetes Care, 2018, 41(8):1783-91.
[21] Yanase T, Yanagita I, Muta K, et al. Fraity in elderly diabetes patients [J]. Endocr J, 2018, 65(1):1-11.
[22] SILBERT R, SALCIDO-MONTENEGRO A, RODRIGUEZ GUTIERREZ R, et al. Hypoglycemia among patients with type 2 diabetes: Epidemiology, risk factors and prevention strategies [J]. Current Diabetes Reports, 2018, 18(8):53.
[23] Jin X, Sun ZH, Xi SG, et al. Clinical observation of changes of blood glucose tolerance threshold in diabetic patients [J]. Chin J Experimental Diagnostics, 2008, 12(12):1510-12.
[24] Zhang YR. Clinical observation of hypoglycemia in diabetic patients in the process of blood glucose standard [J]. Chin J Practical Diagnosis & Therapy, 2005, 19(8):604.
[25] Nielsen LR, Pedersen-Bjergaard U, Thorsteinsson B, et al. Hypoglycemia in pregnant women with type 1 diabetes: predictors and role of metabolic control [J]. Diabetes Care, 2008, 31(1):9-14.
[26] Shi HL, Li Y, Liu SY, et al. Effects of four types of insulin intensive treatment on blood glucose control and vascular endothelial function in newly diagnosed type 2 diabetes mellitus [J]. Chinese Journal of Endocrinology and Metabolism, 2012(06):496-98.
[27] Pickup JC, Sutton AJ. Severe hypoglycaemia and glycaemic control in type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion [J]. Diabet Med, 2008, 25:765-74.
Shufang Wang, Liangyu Tang, Zefen Lu, Jingjing Sun. Status of Hypoglycemia in Insulin Intensive Treatment. International Journal of Medicine Frontiers, 2022, 5(2), 46-50.
Copyright © 2022 Damray Co., Ltd. Privacy Policy | Terms and Conditions
